Market Intelligence chevron_right Pharma & Healthcare chevron_right PD-1 and PD-L1 Inhibitors
Global Report 2021

Global PD-1 and PD-L1 Inhibitors Market Insights and Forecast to 2027

calendar_todayPublished: Nov 2021 descriptionPages: 118 categoryCategory: Pharma & Healthcare
cloud_downloadRequest Sample Report
mailPre-Order Enquiry
local_offerGet Discount 
1 Study Coverage
    1.1 PD-1 and PD-L1 Inhibitors Product Introduction
    1.2 Market by Type
        1.2.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type
        1.4.2 PD-1 Inhibitors
        1.4.3 PD-L1 Inhibitors
    1.3 Market by Application
        1.3.1 Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application
        1.3.2 Solid Tumors
        1.3.3 Blood-related Tumors
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
    2.1 Global PD-1 and PD-L1 Inhibitors Sales Estimates and Forecasts 2016-2027
    2.2 Global PD-1 and PD-L1 Inhibitors Revenue Estimates and Forecasts 2016-2027
    2.3 Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2016 VS 2021 VS 2027
    2.4 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales
        2.4.1 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales (2016-2021)
        2.4.2 Global Top PD-1 and PD-L1 Inhibitors Regions by Sales (2022-2027)
    2.5 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue
        2.5.1 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue (2016-2021)
        2.5.2 Global Top PD-1 and PD-L1 Inhibitors Regions by Revenue (2022-2027)
    2.6 North America
    2.7 Europe
    2.8 Asia-Pacific
    2.9 Latin America
    2.10 Middle East & Africa
3 Competition by Manufacturers
    3.1 Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers
        3.1.1 Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Sales (2016-2021)
        3.1.2 Global Top PD-1 and PD-L1 Inhibitors Manufacturers Market Share by Sales (2016-2021)
        3.1.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Sales in 2020
    3.2 Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers
        3.2.1 Global Top PD-1 and PD-L1 Inhibitors Manufacturers by Revenue (2016-2021)
        3.2.2 Global Top PD-1 and PD-L1 Inhibitors Manufacturers Market Share by Revenue (2016-2021)
        3.2.3 Global Top 10 and Top 5 Companies by PD-1 and PD-L1 Inhibitors Revenue in 2020
    3.3 Global PD-1 and PD-L1 Inhibitors Sales Price by Manufacturers
    3.4 Analysis of Competitive Landscape
        3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
        3.4.2 Global PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
        3.4.3 Global PD-1 and PD-L1 Inhibitors Manufacturers Geographical Distribution
    3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
    4.1 Global PD-1 and PD-L1 Inhibitors Sales by Type
        4.1.1 Global PD-1 and PD-L1 Inhibitors Historical Sales by Type (2016-2021)
        4.1.2 Global PD-1 and PD-L1 Inhibitors Forecasted Sales by Type (2022-2027)
        4.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    4.2 Global PD-1 and PD-L1 Inhibitors Revenue by Type
        4.2.1 Global PD-1 and PD-L1 Inhibitors Historical Revenue by Type (2016-2021)
        4.2.2 Global PD-1 and PD-L1 Inhibitors Forecasted Revenue by Type (2022-2027)
        4.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    4.3 Global PD-1 and PD-L1 Inhibitors Price by Type
        4.3.1 Global PD-1 and PD-L1 Inhibitors Price by Type (2016-2021)
        4.3.2 Global PD-1 and PD-L1 Inhibitors Price Forecast by Type (2022-2027)
5 Market Size by Application
    5.1 Global PD-1 and PD-L1 Inhibitors Sales by Application
        5.1.1 Global PD-1 and PD-L1 Inhibitors Historical Sales by Application (2016-2021)
        5.1.2 Global PD-1 and PD-L1 Inhibitors Forecasted Sales by Application (2022-2027)
        5.1.3 Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    5.2 Global PD-1 and PD-L1 Inhibitors Revenue by Application
        5.2.1 Global PD-1 and PD-L1 Inhibitors Historical Revenue by Application (2016-2021)
        5.2.2 Global PD-1 and PD-L1 Inhibitors Forecasted Revenue by Application (2022-2027)
        5.2.3 Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    5.3 Global PD-1 and PD-L1 Inhibitors Price by Application
        5.3.1 Global PD-1 and PD-L1 Inhibitors Price by Application (2016-2021)
        5.3.2 Global PD-1 and PD-L1 Inhibitors Price Forecast by Application (2022-2027)

6 North America
    6.1 North America PD-1 and PD-L1 Inhibitors Market Size by Type
        6.1.1 North America PD-1 and PD-L1 Inhibitors Sales by Type (2016-2027)
        6.1.2 North America PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2027)
    6.2 North America PD-1 and PD-L1 Inhibitors Market Size by Application
        6.2.1 North America PD-1 and PD-L1 Inhibitors Sales by Application (2016-2027)
        6.2.2 North America PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2027)
    6.3 North America PD-1 and PD-L1 Inhibitors Market Size by Country
        6.3.1 North America PD-1 and PD-L1 Inhibitors Sales by Country (2016-2027)
        6.3.2 North America PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2027)
        6.3.3 U.S.
        6.3.4 Canada
7 Europe
    7.1 Europe PD-1 and PD-L1 Inhibitors Market Size by Type
        7.1.1 Europe PD-1 and PD-L1 Inhibitors Sales by Type (2017-2027)
        7.1.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2017-2027)
    7.2 Europe PD-1 and PD-L1 Inhibitors Market Size by Application
        7.2.1 Europe PD-1 and PD-L1 Inhibitors Sales by Application (2017-2027)
        7.2.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2017-2027)
    7.3 Europe PD-1 and PD-L1 Inhibitors Market Size by Country
        7.3.1 Europe PD-1 and PD-L1 Inhibitors Sales by Country (2017-2027)
        7.3.2 Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2017-2027)
        7.3.3 Germany
        7.3.4 France
        7.3.5 U.K.
        7.3.6 Italy
        7.3.7 Russia
8 Asia Pacific
    8.1 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Type
        8.1.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Type (2018-2027)
        8.1.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Type (2018-2027)
    8.2 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Application
        8.2.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Application (2018-2027)
        8.2.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Application (2018-2027)
    8.3 Asia Pacific PD-1 and PD-L1 Inhibitors Market Size by Region
        8.3.1 Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region (2018-2027)
        8.3.2 Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region (2018-2027)
        8.3.3 China
        8.3.4 Japan
        8.3.5 South Korea
        8.3.6 India
        8.3.7 Australia
        8.3.8 Taiwan
        8.3.9 Indonesia
        8.3.10 Thailand
        8.3.11 Malaysia
        8.3.12 Philippines
9 Latin America
    9.1 Latin America PD-1 and PD-L1 Inhibitors Market Size by Type
        9.1.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Type (2019-2027)
        9.1.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Type (2019-2027)
    9.2 Latin America PD-1 and PD-L1 Inhibitors Market Size by Application
        9.2.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Application (2019-2027)
        9.2.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Application (2019-2027)
    9.3 Latin America PD-1 and PD-L1 Inhibitors Market Size by Country
        9.3.1 Latin America PD-1 and PD-L1 Inhibitors Sales by Country (2019-2027)
        9.3.2 Latin America PD-1 and PD-L1 Inhibitors Revenue by Country (2019-2027)
        9.3.3 Mexico
        9.3.4 Brazil
        9.3.5 Argentina
6 Middle East and Africa
    6.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Type
        6.1.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Type (2016-2027)
        6.1.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2027)
    6.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Application
        6.2.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Application (2016-2027)
        6.2.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2027)
    6.3 Middle East and Africa PD-1 and PD-L1 Inhibitors Market Size by Country
        6.3.1 Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2016-2027)
        6.3.2 Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2027)
        6.3.3 Turkey
        6.3.4 Saudi Arabia
        6.3.5 UAE

11 Company Profiles
    11.1 Merck
        11.1.1 Merck Corporation Information
        11.1.2 Merck Overview
        11.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.1.4 Merck PD-1 and PD-L1 Inhibitors Product Description
        11.1.5 Merck Related Developments
    11.2 Bristol-Myers Squibb
        11.2.1 Bristol-Myers Squibb Corporation Information
        11.2.2 Bristol-Myers Squibb Overview
        11.2.3 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.2.4 Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product Description
        11.2.5 Bristol-Myers Squibb Related Developments
    11.3 Roche
        11.3.1 Roche Corporation Information
        11.3.2 Roche Overview
        11.3.3 Roche PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.3.4 Roche PD-1 and PD-L1 Inhibitors Product Description
        11.3.5 Roche Related Developments
    11.4 AstraZeneca
        11.4.1 AstraZeneca Corporation Information
        11.4.2 AstraZeneca Overview
        11.4.3 AstraZeneca PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.4.4 AstraZeneca PD-1 and PD-L1 Inhibitors Product Description
        11.4.5 AstraZeneca Related Developments
    11.5 Ono Pharmaceutical
        11.5.1 Ono Pharmaceutical Corporation Information
        11.5.2 Ono Pharmaceutical Overview
        11.5.3 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.5.4 Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product Description
        11.5.5 Ono Pharmaceutical Related Developments
    11.6 Regeneron
        11.6.1 Regeneron Corporation Information
        11.6.2 Regeneron Overview
        11.6.3 Regeneron PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.6.4 Regeneron PD-1 and PD-L1 Inhibitors Product Description
        11.6.5 Regeneron Related Developments
    11.7 Innovent
        11.7.1 Innovent Corporation Information
        11.7.2 Innovent Overview
        11.7.3 Innovent PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.7.4 Innovent PD-1 and PD-L1 Inhibitors Product Description
        11.7.5 Innovent Related Developments
    11.8 Hengrui Medicine
        11.8.1 Hengrui Medicine Corporation Information
        11.8.2 Hengrui Medicine Overview
        11.8.3 Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.8.4 Hengrui Medicine PD-1 and PD-L1 Inhibitors Product Description
        11.8.5 Hengrui Medicine Related Developments
    11.9 Junshi Biosciences
        11.9.1 Junshi Biosciences Corporation Information
        11.9.2 Junshi Biosciences Overview
        11.9.3 Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.9.4 Junshi Biosciences PD-1 and PD-L1 Inhibitors Product Description
        11.9.5 Junshi Biosciences Related Developments
    11.10 Merck KGaA
        11.10.1 Merck KGaA Corporation Information
        11.10.2 Merck KGaA Overview
        11.10.3 Merck KGaA PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.10.4 Merck KGaA PD-1 and PD-L1 Inhibitors Product Description
        11.10.5 Merck KGaA Related Developments
    11.1 Merck
        11.1.1 Merck Corporation Information
        11.1.2 Merck Overview
        11.1.3 Merck PD-1 and PD-L1 Inhibitors Sales, Price, Revenue and Gross Margin (2016-2021)
        11.1.4 Merck PD-1 and PD-L1 Inhibitors Product Description
        11.1.5 Merck Related Developments

12 Value Chain and Sales Channels Analysis
    12.1 PD-1 and PD-L1 Inhibitors Value Chain Analysis
    12.2 PD-1 and PD-L1 Inhibitors Key Raw Materials
        12.2.1 Key Raw Materials
        12.2.2 Raw Materials Key Suppliers
    12.3 PD-1 and PD-L1 Inhibitors Production Mode & Process
    12.4 PD-1 and PD-L1 Inhibitors Sales and Marketing
        12.4.1 PD-1 and PD-L1 Inhibitors Sales Channels
        12.4.2 PD-1 and PD-L1 Inhibitors Distributors
    12.5 PD-1 and PD-L1 Inhibitors Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
    13.1 PD-1 and PD-L1 Inhibitors Industry Trends
    13.2 PD-1 and PD-L1 Inhibitors Market Drivers
    13.3 PD-1 and PD-L1 Inhibitors Market Challenges
    13.4 PD-1 and PD-L1 Inhibitors Market Restraints

14 Key Findings in The Global PD-1 and PD-L1 Inhibitors Study
15 Appendix
    15.1 Research Methodology
        15.1.1 Methodology/Research Approach
        15.1.2 Data Source
    15.2 Author Details
    15.3 Disclaimer
List of Tables
    Table 1. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
    Table 2. Major Manufacturers of PD-1 Inhibitors
    Table 3. Major Manufacturers of PD-L1 Inhibitors
    Table 4. Global PD-1 and PD-L1 Inhibitors Market Size Growth Rate by Application, 2016 VS 2021 VS 2027 (US$ Million)
    Table 5. Global PD-1 and PD-L1 Inhibitors Revenue by Region: 2016 VS 2021 VS 2027 (US$ Million)
    Table 6. Global PD-1 and PD-L1 Inhibitors Sales by Region (2016-2021) & (L)
    Table 7. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2016-2021)
    Table 8. Global PD-1 and PD-L1 Inhibitors Sales by Region (2016-2021) & (L)
    Table 9. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2022-2027)
    Table 10. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2016-2021) & (US$ Million)
    Table 11. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2016-2021)
    Table 12. Global PD-1 and PD-L1 Inhibitors Revenue by Region (2022-2027) & (US$ Million)
    Table 13. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region (2022-2027)
    Table 14. Global PD-1 and PD-L1 Inhibitors Sales by Manufacturers (2016-2021) & (L)
    Table 15. Global PD-1 and PD-L1 Inhibitors Sales Share by Manufacturers (2016-2021)
    Table 16. Global PD-1 and PD-L1 Inhibitors Revenue by Manufacturers (2016-2021) & (US$ Million)
    Table 17. Global PD-1 and PD-L1 Inhibitors Revenue Share by Manufacturers (2016-2021)
    Table 18. PD-1 and PD-L1 Inhibitors Price by Manufacturers 2016-2021 (USD/ml)
    Table 19. Global PD-1 and PD-L1 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 20. Global PD-1 and PD-L1 Inhibitors by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PD-1 and PD-L1 Inhibitors as of 2020)
    Table 21. PD-1 and PD-L1 Inhibitors Manufacturing Base Distribution and Headquarters
    Table 22. Manufacturers PD-1 and PD-L1 Inhibitors Product Offered
    Table 23. Date of Manufacturers Enter into PD-1 and PD-L1 Inhibitors Market
    Table 24. Mergers & Acquisitions, Expansion Plans
    Table 25. Global PD-1 and PD-L1 Inhibitors Sales by Type (2016-2021) & (L)
    Table 26. Global PD-1 and PD-L1 Inhibitors Sales by Type (2022-2027) & (L)
    Table 27. Global PD-1 and PD-L1 Inhibitors Sales Share by Type (2016-2021)
    Table 28. Global PD-1 and PD-L1 Inhibitors Sales Share by Type (2022-2027)
    Table 29. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2021) & (US$ Million)
    Table 30. Global PD-1 and PD-L1 Inhibitors Revenue by Type (2022-2027) & (US$ Million)
    Table 31. Global PD-1 and PD-L1 Inhibitors Revenue Share by Type (2016-2021)
    Table 32. Global PD-1 and PD-L1 Inhibitors Revenue Share by Type (2022-2027)
    Table 33. PD-1 and PD-L1 Inhibitors Price by Type (2016-2021) & (USD/ml)
    Table 34. Global PD-1 and PD-L1 Inhibitors Price Forecast by Type (2022-2027) & (USD/ml)
    Table 35. Global PD-1 and PD-L1 Inhibitors Sales by Application (2016-2021) & (L)
    Table 36. Global PD-1 and PD-L1 Inhibitors Sales by Application (2022-2027) & (L)
    Table 37. Global PD-1 and PD-L1 Inhibitors Sales Share by Application (2016-2021)
    Table 38. Global PD-1 and PD-L1 Inhibitors Sales Share by Application (2022-2027)
    Table 39. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2021) & (US$ Million)
    Table 40. Global PD-1 and PD-L1 Inhibitors Revenue by Application (2022-2027) & (US$ Million)
    Table 41. Global PD-1 and PD-L1 Inhibitors Revenue Share by Application (2016-2021)
    Table 42. Global PD-1 and PD-L1 Inhibitors Revenue Share by Application (2022-2027)
    Table 43. PD-1 and PD-L1 Inhibitors Price by Application (2016-2021) & (USD/ml)
    Table 44. Global PD-1 and PD-L1 Inhibitors Price Forecast by Application (2022-2027) & (USD/ml)
    Table 45. North America PD-1 and PD-L1 Inhibitors Sales by Type (2016-2021) & (L)
    Table 46. North America PD-1 and PD-L1 Inhibitors Sales by Type (2022-2027) & (L)
    Table 47. North America PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2021) & (US$ Million)
    Table 48. North America PD-1 and PD-L1 Inhibitors Revenue by Type (2022-2027) & (US$ Million)
    Table 49. North America PD-1 and PD-L1 Inhibitors Sales by Application (2016-2021) & (L)
    Table 50. North America PD-1 and PD-L1 Inhibitors Sales by Application (2022-2027) & (L)
    Table 51. North America PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2021) & (US$ Million)
    Table 52. North America PD-1 and PD-L1 Inhibitors Revenue by Application (2022-2027) & (US$ Million)
    Table 53. North America PD-1 and PD-L1 Inhibitors Sales by Country (2016-2021) & (L)
    Table 54. North America PD-1 and PD-L1 Inhibitors Sales by Country (2022-2027) & (L)
    Table 55. North America PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2021) & (US$ Million)
    Table 56. North America PD-1 and PD-L1 Inhibitors Revenue by Country (2022-2027) & (US$ Million)
    Table 57. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2016-2021) & (L)
    Table 58. Europe PD-1 and PD-L1 Inhibitors Sales by Type (2022-2027) & (L)
    Table 59. Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2021) & (US$ Million)
    Table 60. Europe PD-1 and PD-L1 Inhibitors Revenue by Type (2022-2027) & (US$ Million)
    Table 61. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2016-2021) & (L)
    Table 62. Europe PD-1 and PD-L1 Inhibitors Sales by Application (2022-2027) & (L)
    Table 63. Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2021) & (US$ Million)
    Table 64. Europe PD-1 and PD-L1 Inhibitors Revenue by Application (2022-2027) & (US$ Million)
    Table 65. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2016-2021) & (L)
    Table 66. Europe PD-1 and PD-L1 Inhibitors Sales by Country (2022-2027) & (L)
    Table 67. Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2021) & (US$ Million)
    Table 68. Europe PD-1 and PD-L1 Inhibitors Revenue by Country (2022-2027) & (US$ Million)
    Table 69. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Type (2016-2021) & (L)
    Table 70. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Type (2022-2027) & (L)
    Table 71. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2021) & (US$ Million)
    Table 72. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Type (2022-2027) & (US$ Million)
    Table 73. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Application (2016-2021) & (L)
    Table 74. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Application (2022-2027) & (L)
    Table 75. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2021) & (US$ Million)
    Table 76. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Application (2022-2027) & (US$ Million)
    Table 77. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region (2016-2021) & (L)
    Table 78. Asia Pacific PD-1 and PD-L1 Inhibitors Sales by Region (2022-2027) & (L)
    Table 79. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region (2016-2021) & (US$ Million)
    Table 80. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue by Region (2022-2027) & (US$ Million)
    Table 81. Latin America PD-1 and PD-L1 Inhibitors Sales by Type (2016-2021) & (L)
    Table 82. Latin America PD-1 and PD-L1 Inhibitors Sales by Type (2022-2027) & (L)
    Table 83. Latin America PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2021) & (US$ Million)
    Table 84. Latin America PD-1 and PD-L1 Inhibitors Revenue by Type (2022-2027) & (US$ Million)
    Table 85. Latin America PD-1 and PD-L1 Inhibitors Sales by Application (2016-2021) & (L)
    Table 86. Latin America PD-1 and PD-L1 Inhibitors Sales by Application (2022-2027) & (L)
    Table 87. Latin America PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2021) & (US$ Million)
    Table 88. Latin America PD-1 and PD-L1 Inhibitors Revenue by Application (2022-2027) & (US$ Million)
    Table 89. Latin America PD-1 and PD-L1 Inhibitors Sales by Country (2016-2021) & (L)
    Table 90. Latin America PD-1 and PD-L1 Inhibitors Sales by Country (2022-2027) & (L)
    Table 91. Latin America PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2021) & (US$ Million)
    Table 92. Latin America PD-1 and PD-L1 Inhibitors Revenue by Country (2022-2027) & (US$ Million)
    Table 93. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Type (2016-2021) & (L)
    Table 94. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Type (2022-2027) & (L)
    Table 95. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Type (2016-2021) & (US$ Million)
    Table 96. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Type (2022-2027) & (US$ Million)
    Table 97. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Application (2016-2021) & (L)
    Table 98. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Application (2022-2027) & (L)
    Table 99. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Application (2016-2021) & (US$ Million)
    Table 100. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Application (2022-2027) & (US$ Million)
    Table 101. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2016-2021) & (L)
    Table 102. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales by Country (2022-2027) & (L)
    Table 103. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2016-2021) & (US$ Million)
    Table 104. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue by Country (2022-2027) & (US$ Million)
    Table 105. Merck Corporation Information
    Table 106. Merck Description and Major Businesses
    Table 107. Merck PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 108. Merck PD-1 and PD-L1 Inhibitors Product
    Table 109. Merck Recent Developments
    Table 110. Bristol-Myers Squibb Corporation Information
    Table 111. Bristol-Myers Squibb Description and Major Businesses
    Table 112. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 113. Bristol-Myers Squibb PD-1 and PD-L1 Inhibitors Product
    Table 114. Bristol-Myers Squibb Recent Developments
    Table 115. Roche Corporation Information
    Table 116. Roche Description and Major Businesses
    Table 117. Roche PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 118. Roche PD-1 and PD-L1 Inhibitors Product
    Table 119. Roche Recent Developments
    Table 120. AstraZeneca Corporation Information
    Table 121. AstraZeneca Description and Major Businesses
    Table 122. AstraZeneca PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 123. AstraZeneca PD-1 and PD-L1 Inhibitors Product
    Table 124. AstraZeneca Recent Developments
    Table 125. Ono Pharmaceutical Corporation Information
    Table 126. Ono Pharmaceutical Description and Major Businesses
    Table 127. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 128. Ono Pharmaceutical PD-1 and PD-L1 Inhibitors Product
    Table 129. Ono Pharmaceutical Recent Developments
    Table 130. Regeneron Corporation Information
    Table 131. Regeneron Description and Major Businesses
    Table 132. Regeneron PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 133. Regeneron PD-1 and PD-L1 Inhibitors Product
    Table 134. Regeneron Recent Developments
    Table 135. Innovent Corporation Information
    Table 136. Innovent Description and Major Businesses
    Table 137. Innovent PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 138. Innovent PD-1 and PD-L1 Inhibitors Product
    Table 139. Innovent Recent Developments
    Table 140. Hengrui Medicine Corporation Information
    Table 141. Hengrui Medicine Description and Major Businesses
    Table 142. Hengrui Medicine PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 143. Hengrui Medicine PD-1 and PD-L1 Inhibitors Product
    Table 144. Hengrui Medicine Recent Developments
    Table 145. Junshi Biosciences Corporation Information
    Table 146. Junshi Biosciences Description and Major Businesses
    Table 147. Junshi Biosciences PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 148. Junshi Biosciences PD-1 and PD-L1 Inhibitors Product
    Table 149. Junshi Biosciences Recent Developments
    Table 150. Merck KGaA Corporation Information
    Table 151. Merck KGaA Description and Major Businesses
    Table 152. Merck KGaA PD-1 and PD-L1 Inhibitors Sales (L), Revenue (US$ Million), Price (USD/ml) and Gross Margin (2016-2021)
    Table 153. Merck KGaA PD-1 and PD-L1 Inhibitors Product
    Table 154. Merck KGaA Recent Developments
    Table 155. Key Raw Materials Lists
    Table 156. Raw Materials Key Suppliers Lists
    Table 157. PD-1 and PD-L1 Inhibitors Distributors List
    Table 158. PD-1 and PD-L1 Inhibitors Customers List
    Table 159. PD-1 and PD-L1 Inhibitors Market Trends
    Table 160. PD-1 and PD-L1 Inhibitors Market Drivers
    Table 161. PD-1 and PD-L1 Inhibitors Market Challenges
    Table 162. PD-1 and PD-L1 Inhibitors Market Restraints
    Table 163. Research Programs/Design for This Report
    Table 164. Key Data Information from Secondary Sources
    Table 165. Key Data Information from Primary Sources
List of Figures
    Figure 1. PD-1 and PD-L1 Inhibitors Product Picture
    Figure 2. Global PD-1 and PD-L1 Inhibitors Market Share by Type in 2020 & 2027
    Figure 3. PD-1 Inhibitors Product Picture
    Figure 4. PD-L1 Inhibitors Product Picture
    Figure 5. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application in 2020 & 2027
    Figure 6. Solid Tumors
    Figure 7. Blood-related Tumors
    Figure 8. PD-1 and PD-L1 Inhibitors Report Years Considered
    Figure 9. Global PD-1 and PD-L1 Inhibitors Sales 2016-2027 (L)
    Figure 10. Global PD-1 and PD-L1 Inhibitors Revenue, (US$ Million), 2016 VS 2021 VS 2027
    Figure 11. Global PD-1 and PD-L1 Inhibitors Revenue 2016-2027 (US$ Million)
    Figure 12. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Region in Percentage: 2020 Versus 2027
    Figure 13. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2016-2021)
    Figure 14. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Region (2022-2027)
    Figure 15. North America PD-1 and PD-L1 Inhibitors Sales YoY (2016-2027) & (L)
    Figure 16. North America PD-1 and PD-L1 Inhibitors Revenue YoY (2016-2027) & (US$ Million)
    Figure 17. Europe PD-1 and PD-L1 Inhibitors Sales YoY (2016-2027) & (L)
    Figure 18. Europe PD-1 and PD-L1 Inhibitors Revenue YoY (2016-2027) & (US$ Million)
    Figure 19. Asia-Pacific PD-1 and PD-L1 Inhibitors Sales YoY (2016-2027) & (L)
    Figure 20. Asia-Pacific PD-1 and PD-L1 Inhibitors Revenue YoY (2016-2027) & (US$ Million)
    Figure 21. Latin America PD-1 and PD-L1 Inhibitors Sales YoY (2016-2027) & (L)
    Figure 22. Latin America PD-1 and PD-L1 Inhibitors Revenue YoY (2016-2027) & (US$ Million)
    Figure 23. Middle East & Africa PD-1 and PD-L1 Inhibitors Sales YoY (2016-2027) & (L)
    Figure 24. Middle East & Africa PD-1 and PD-L1 Inhibitors Revenue YoY (2016-2027) & (US$ Million)
    Figure 25. The Top 10 and Top 5 Players Market Share by PD-1 and PD-L1 Inhibitors Sales in 2020
    Figure 26. The Top 10 and Top 5 Players Market Share by PD-1 and PD-L1 Inhibitors Revenue in 2020
    Figure 27. PD-1 and PD-L1 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2016 VS 2020
    Figure 28. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    Figure 29. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    Figure 30. Global PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    Figure 31. Global PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    Figure 32. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    Figure 33. North America PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    Figure 34. North America PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    Figure 35. North America PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    Figure 36. North America PD-1 and PD-L1 Inhibitors Sales Share by Country (2016-2027)
    Figure 37. North America PD-1 and PD-L1 Inhibitors Revenue Share by Country (2016-2027)
    Figure 38. U.S. PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 39. Canada PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 40. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    Figure 41. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    Figure 42. Europe PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    Figure 43. Europe PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    Figure 44. Europe PD-1 and PD-L1 Inhibitors Sales Share by Country (2016-2027)
    Figure 45. Europe PD-1 and PD-L1 Inhibitors Revenue Share by Country (2016-2027)
    Figure 46. Germany PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 47. France PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 48. U.K. PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 49. Italy PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 50. Russia PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 51. Asia Pacific PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    Figure 52. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    Figure 53. Asia Pacific PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    Figure 54. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    Figure 55. Asia Pacific PD-1 and PD-L1 Inhibitors Sales Share by Region (2016-2027)
    Figure 56. Asia Pacific PD-1 and PD-L1 Inhibitors Revenue Share by Region (2016-2027)
    Figure 57. China PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 58. Japan PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 59. South Korea PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 60. India PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 61. Australia PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 62. Taiwan PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 63. Indonesia PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 64. Thailand PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 65. Malaysia PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 66. Philippines PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 67. Latin America PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    Figure 68. Latin America PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    Figure 69. Latin America PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    Figure 70. Latin America PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    Figure 71. Latin America PD-1 and PD-L1 Inhibitors Sales Share by Country (2016-2027)
    Figure 72. Latin America PD-1 and PD-L1 Inhibitors Revenue Share by Country (2016-2027)
    Figure 73. Mexico PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 74. Brazil PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 75. Argentina PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 76. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Type (2016-2027)
    Figure 77. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Type (2016-2027)
    Figure 78. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Market Share by Application (2016-2027)
    Figure 79. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Market Share by Application (2016-2027)
    Figure 80. Middle East and Africa PD-1 and PD-L1 Inhibitors Sales Share by Country (2016-2027)
    Figure 81. Middle East and Africa PD-1 and PD-L1 Inhibitors Revenue Share by Country (2016-2027)
    Figure 82. Turkey PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 83. Saudi Arabia PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 84. UAE PD-1 and PD-L1 Inhibitors Revenue (2016-2027) & (US$ Million)
    Figure 85. PD-1 and PD-L1 Inhibitors Value Chain
    Figure 86. PD-1 and PD-L1 Inhibitors Production Process
    Figure 87. Channels of Distribution
    Figure 88. Distributors Profiles
    Figure 89. Bottom-up and Top-down Approaches for This Report
    Figure 90. Data Triangulation
    Figure 91. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Merck
Bristol-Myers Squibb
Roche
AstraZeneca
Ono Pharmaceutical
Regeneron
Innovent
Hengrui Medicine
Junshi Biosciences
Merck KGaA

Frequently Asked Questions

What is the USP of the report? expand_more
PD-1 and PD-L1 Inhibitors report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
What are the key content of the report? expand_more
PD-1 and PD-L1 Inhibitors report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
What are the value propositions and opportunities offered in this market research report? expand_more
PD-1 and PD-L1 Inhibitors report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.